Tommaso Iannitti1,2, Julio César Morales-Medina3, Alessandro Coacci4,5, Beniamino Palmieri4,5. 1. School of Biomedical Sciences, University of Leeds, Mount Preston Street, Garstang building, Leeds, LS2 9JT, UK. tommaso.iannitti@gmail.com. 2. Poliambulatorio del Secondo Parere, Modena, Italy. tommaso.iannitti@gmail.com. 3. Centro de Investigación en Reproducción Animal, CINVESTAV, Tlaxcala AP 62, CP, 90000, Mexico. 4. Poliambulatorio del Secondo Parere, Modena, Italy. 5. Department of General Surgery and Surgical Specialties, University of Modena and Reggio Emilia Medical School, Surgical Clinic, Modena, Italy.
Abstract
BACKGROUND: In the field of aesthetic medicine there is an increasing demand for safe and effective hyaluronic acid (HA) fillers to counteract the aging process. METHODS AND AIMS: We designed a study to evaluate the safety and histological biocompatibility of Aliaxin® Global Performance, a cross-linked HA filler and Viscoderm® Skinkò E, a product composed of non-cross-linked HA and a complex including vitamins, antioxidants, amino acids and minerals injected into the skin of guinea pigs. Then, we translated our findings into the clinical setting, administering a combination of these compounds to patients seeking a facial rejuvenation procedure targeting moderate-to-severe wrinkles affecting the nasolabial folds. RESULTS: The animal study showed that the two compounds did not induce any significant inflammatory reactions and increased collagen and elastic fibers in the skin. In the clinical setting, injection of Aliaxin® Global Performance, followed by Viscoderm® Skinkò E, resulted in a higher improvement in nasolabial fold hydration, trans-epidermal water loss and wrinkle aesthetic appearance, if compared with a protocol based on Aliaxin® Global Performance alone. CONCLUSION: In summary, we show evidence on the safety and mechanism underlying two new HA-based compounds of different cross-linkage and composition, proposing that they can be safely used in combination in patients seeking facial rejuvenation procedures with long-lasting efficacy.
BACKGROUND: In the field of aesthetic medicine there is an increasing demand for safe and effective hyaluronic acid (HA) fillers to counteract the aging process. METHODS AND AIMS: We designed a study to evaluate the safety and histological biocompatibility of Aliaxin® Global Performance, a cross-linked HA filler and Viscoderm® Skinkò E, a product composed of non-cross-linked HA and a complex including vitamins, antioxidants, amino acids and minerals injected into the skin of guinea pigs. Then, we translated our findings into the clinical setting, administering a combination of these compounds to patients seeking a facial rejuvenation procedure targeting moderate-to-severe wrinkles affecting the nasolabial folds. RESULTS: The animal study showed that the two compounds did not induce any significant inflammatory reactions and increased collagen and elastic fibers in the skin. In the clinical setting, injection of Aliaxin® Global Performance, followed by Viscoderm® Skinkò E, resulted in a higher improvement in nasolabial fold hydration, trans-epidermal water loss and wrinkle aesthetic appearance, if compared with a protocol based on Aliaxin® Global Performance alone. CONCLUSION: In summary, we show evidence on the safety and mechanism underlying two new HA-based compounds of different cross-linkage and composition, proposing that they can be safely used in combination in patients seeking facial rejuvenation procedures with long-lasting efficacy.
Authors: Andrea Ardizzoni; Rachele G Neglia; Maria C Baschieri; Claudio Cermelli; Manuela Caratozzolo; Elena Righi; Beniamino Palmieri; Elisabetta Blasi Journal: J Mater Sci Mater Med Date: 2011-09-04 Impact factor: 3.896
Authors: Antonietta Stellavato; Anna Virginia Adriana Pirozzi; Stella Donato; Ilaria Scognamiglio; Sabrina Reale; Alba Di Pardo; Stefania Filosa; Valentina Vassallo; Gilberto Bellia; Mario De Rosa; Chiara Schiraldi Journal: Biomed Res Int Date: 2018-06-26 Impact factor: 3.411